Company news
Sernova Biotherapeutics Inc (TSX:SVA) news
Sernova Biotherapeutics Inc news releases on 6ix. Latest, May 1, 2024: Sernova Announces AGM Voting Results
Press releases — page 2
Sernova Announces AGM Voting Results
May 1, 2024
Sernova Provides Organizational Update
April 25, 2024
Sernova Welcomes Dr. Bernd Muehlenweg as Evotec's Nominee for its Board of Directors
April 22, 2024
Sernova Provides Positive Clinical and Platform Portfolio Update
April 2, 2024
Sernova Announces Management Developments
March 11, 2024
Sernova Provides Recap of 2023 Accomplishments and Anticipated 2024 Milestones
January 29, 2024
Sernova Corp. Announces Voting Results of the 2023 Annual General Meeting of Shareholders
April 28, 2023
Concerned Shareholders of Sernova Corp. Wish to Thank All Shareholders
April 25, 2023
Sernova Reminds Shareholders to Vote FOR the Eight Management Director Nominees Using ONLY the WHITE Management Proxy
April 21, 2023
Two Independent Proxy Advisory Firms, Including Glass Lewis & Co. LLC. Recommend Sernova's Shareholders Vote FOR all Management Nominees on Management's White Proxy
April 18, 2023
Concerned Shareholders of Sernova Corp. Stand by their Statements
April 17, 2023
Concerned Shareholders of Sernova Corp. Nominate Two Highly Qualified Directors to the Board
April 3, 2023
Advance Notice Filed with Sernova Corp. for the Nomination of Two Director Nominees
March 22, 2023
Sernova Corp. Announces Change of Auditor
October 24, 2022
Sernova Opens the Market
June 2, 2022
SERNOVA SHARES to Commence Trading on TSX On June 2, 2022
June 1, 2022
Sernova Receives Conditional Approval to Up-list to the Toronto Stock Exchange
May 24, 2022
Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 82nd Scientific Sessions 2022
May 9, 2022
Sernova to Participate in Multiple U.S. Healthcare Investor Conferences
May 5, 2022
Sernova Announces 2022 Annual General Meeting Results
April 29, 2022
Data Safety Monitoring Board Recommends Continuation of Phase 1/2 Clinical Trial with Sernova's Cell Pouch System(TM) in Patients with Type-1 Diabetes
March 17, 2022
Sernova Corp Ranks Among Top 50 Performing Companies on the 2022 TSX Venture List
February 24, 2022
Sernova Announces Peer Reviewed Publication Demonstrating Positive Preclinical Safety and Efficacy Indicators of Its Novel Cell Pouch System(TM) Therapeutic Approach for Treatment of Thyroid Disease
January 27, 2022
Sernova Announces Peer Reviewed Publication Demonstrating Safety and Efficacy of a Novel Cell Pouch Cell Therapy Approach for Treatment of Severe Hemophilia A
January 20, 2022
IIROC Trading Resumption - SVA
January 10, 2022
IIROC Trading Halt - SVA
January 10, 2022
The Principal Investigator in Sernova's Type 1 Diabetes (T1D) Trial Confirms Patients with a History of Hypoglycemia Unawareness Are Now Insulin Independent
January 10, 2022
Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference
January 5, 2022
Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium
December 16, 2021
Sernova Appoints Christopher Barnes as Vice President, Investor Relations & Grants Options/DSUs
December 14, 2021
Sernova Announces Appointment of Executive Chair to Complement its Management Team
December 2, 2021
Sernova to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
November 16, 2021
Sernova: The Ultimate Combination of Two Proven Technologies as Potential Functional Cure for Type 1 Diabetes and Other Chronic Diseases
October 1, 2021
Sernova Engages New York-Based LifeSci Advisors as US Investor Relations Partner
September 29, 2021
Sernova Signs Collaboration Agreement to Advance Conformal Coated Immune Protected Therapeutic Cells for Diabetes with the University of Miami
September 16, 2021
Sernova to Present Corporate Update at Canaccord Genuity's 41st Annual Growth Conference
August 9, 2021
Sernova Announces 2021 Annual Meeting Results: Shareholders Approve Resolutions with Overwhelming Majority
July 5, 2021
Industry Veteran Frank Shannon Joins Sernova as VP Clinical Development and Regulatory Affairs
June 30, 2021
Sernova's Principal Investigator Presents Interim Data and Positive Patient Outcomes of Phase I/II T1D Study at the American Diabetes Association 81st Scientific Sessions
June 28, 2021
Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference
June 7, 2021
Sernova Announces American Transplant Congress 2021 Virtual Connect Abstract Presentation
June 1, 2021
Sernova to Present at Global Partnership Family Office -- HealthCare & Biotechnology TSX Showcase
May 17, 2021
Sernova Announces the Nomination of Seasoned Pharma Executive Dr. Mohammad Azab to its Board of Directors
May 4, 2021
Sernova KOL Event Highlights Novel Cell Therapy Approach for the Potential Treatment of Thyroid Disease
April 28, 2021
Sernova to Host a Virtual Key Opinion Leader Event on Thyroid Disease and the Potential for its Cell Therapy as a Novel Treatment Approach
April 21, 2021
Sernova Appoints Internationally Renowned Thyroid Disease Expert Dr. Sam Wiseman to its Scientific Advisory Board
April 14, 2021
Sernova Announces Presentation at the American Diabetes Association 81st Scientific Sessions
April 6, 2021
Sernova's Story Front-Page Nationally via Canada's Largest Newspaper Independent
March 23, 2021
Sernova Provides Positive Outlook Regarding the Development of Its Innovative Therapeutics Platform Technology for Chronic Diseases
March 15, 2021
2020 - The Emergence of Significant Scientific Medical Advances Where to Watch Next - Regenerative Medicine
March 8, 2021